Recent Quotes (30 days)

You have no recent quotes
chg | %

Roche Holding Ltd. (ADR)  

(Public, OTCMKTS:RHHBY)   Watch this stock  
Find more results for PINK:RHHBY
31.01
+0.22 (0.71%)
Delayed:   1:50pm GMT-4
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 30.86 - 31.02
52 week 29.89 - 35.13
Open 30.92
Vol / Avg. 461,077.00/861,514.00
Mkt cap 214,706.60M
P/E 23.03
Div/yield 1.02/3.28
EPS 1.35
Shares 692.02M
Beta 0.73
Inst. own 16%
Nov 22, 2016
Roche Holding AG at Exane SRI Conference Add to calendar
Nov 18, 2016
Roche Holding AG at JPMorgan CEO Conference Call Series Add to calendar
Nov 17, 2016
Roche Holding AG at Jefferies Healthcare Conference Add to calendar
Nov 16, 2016
Roche Holding AG at UBS Global Healthcare Conference Add to calendar
Oct 20, 2016
Q3 2016 Roche Holding AG Earnings Release - 1:00am GMT-4 - Add to calendar
Oct 20, 2016
Q3 2016 Roche Holding AG Earnings Call Add to calendar
Sep 21, 2016
Roche Holding AG at Sanford C Bernstein Pan European Conference Add to calendar
Sep 16, 2016
Roche Holding AG at UBS Best of Switzerland Conference Add to calendar
Sep 15, 2016
Roche Holding AG at Bank of America Merrill Lynch Healthcare Conference Add to calendar
Sep 12, 2016
Roche Holding AG at Morgan Stanley Global Healthcare Conference Add to calendar
  

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 21.85% 18.81%
Operating margin 32.51% 27.89%
EBITD margin - 40.92%
Return on average assets 14.51% 11.97%
Return on average equity 54.40% 43.70%
Employees 91,747 -
CDP Score - 100 A

Address

Grenzacherstr. 124
BASEL, 4058
Switzerland
+41-9-732354295 (Phone)

Website links

External links

Description

Roche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai. Its Diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. It develops medicines for the disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its product portfolio consists of Pharmaceuticals, Solutions for Diagnostics and Products for Researchers. Its Pharmaceutical products include ACTEMRA and CellCept. Its Solutions for Diagnostics products include Accu-Chek Active System and Accu-Chek Aviva Nano System. The Company's Products for Researchers include Cedex HiRes and Genome Sequencer FLX System.

Officers and directors

Severin Schwan Chairman of the Corporate Executive Committee, Chief Executive Officer, Director
Age: 49
Alan Hippe Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer
Age: 49
Stephan Feldhaus Member of the Enlarged Corporate Executive Committee, Head Group Communications
Age: 54
Sophie Kornowski-Bonnet Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Age: 52
Osamu Nagayama Member of the Enlarged Corporate Executive Committee, President and Chief Executive Officer of Chugai
Age: 68
John C. Reed M.D., Ph.D. Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Age: 58
Michael David Varney Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Age: 58
Urs Jaisli Chief Compliance Officer
Age: 60
Gottlieb A. Keller Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors
Age: 62
Silvia Ayyoubi Member of the Corporate Executive Committee, Head Group Human Resources
Age: 63